Ovarian Neoplasms
274
44
56
129
Key Insights
Highlights
Success Rate
75% trial completion
Published Results
52 trials with published results (19%)
Research Maturity
129 completed trials (47% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
15.3%
42 terminated out of 274 trials
75.4%
-11.1% vs benchmark
11%
31 trials in Phase 3/4
40%
52 of 129 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 129 completed trials
Clinical Trials (274)
A Study of DM002 in Patients With Advanced Solid Tumors
A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Mo-Rez in First- Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficient Ovarian Cancer (Non-HRd OC) [BEHOLD-Ovarian03]
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
Centralization and Oncologic Outcomes in Ovarian Cancer
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)
A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02)
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
A Study of SGN-MesoC2 in Advanced Solid Tumors
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Blood-Based Minimal Residual Disease in Advanced Epithelial Ovarian Cancer After 1st Line Therapy
Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovarian Cancer